<DOC>
	<DOCNO>NCT00890825</DOCNO>
	<brief_summary>The purpose study compare efficacy AZD6244 combination docetaxel versus docetaxel alone patient KRAS mutation positive locally advanced metastatic non small cell lung cancer .</brief_summary>
	<brief_title>Comparison AZD6244 Combination With Docetaxel Versus Docetaxel Alone KRAS Mutation Positive Non Small Cell Lung Cancer ( NSCLC ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Locally advanced metastatic non small cell lung cancer ( IIIBIV ) Failure first line anticancer therapy ( either radiological documentation disease progression due toxicity ) advance disease subsequent relapse disease follow first line therapy Tumour sample confirm KRAS mutation positive ( Note : Sample must available upon enrolment ship AZ appoint central laboratory , mutation status confirm locally AstraZeneca agree local laboratory use agree methodology , mutation status confirm accredit ( eg CLIA certify ) commercial laboratory ( eg Genzyme Lab 21 ) . Received &gt; 1 prior anticancer therapy advance metastatic non small cell lung cancer ( exclude radiotherapy ) Prior treatment MEK inhibitor docetaxel contain regimen ( prior treatment paclitaxel acceptable ) Having receive investigational drug within 30 day start treatment , recover side effect investigational drug Brain metastases spinal cord compression unless asymptomatic , treat stable steroid anticonvulsant least 1 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Non small cell lung cancer ( NSCLC )</keyword>
	<keyword>KRAS mutation</keyword>
</DOC>